Duchenne Muscular Dystrophy Drugs Market by Drug Type, Administration Method, End-Use

Description

List of Tables

[182 Pages Report] The Duchenne Muscular Dystrophy Drugs Market size was estimated at USD 1.57 billion in 2023 and expected to reach USD 1.70 billion in 2024, at a CAGR 8.61% to reach USD 2.80 billion by 2030.

The Duchenne muscular dystrophy (DMD) drugs market focuses on the sales, development, and production of pharmaceuticals specifically aimed at treating DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. Advancements in genetic research and breakthroughs in understanding the genetic basis of DMD are leading to more targeted and effective treatments, contributing to the market expansion. Higher global healthcare expenditure enables better treatment access for DMD, contributing to market growth. Funding and initiatives by governments and non-profit organizations boost research and development efforts, enhancing the market adoption of DMD drugs. Stringent regulatory requirements for drug approval and market introduction may delay access to innovative treatments, posing challenges in the market space. Moreover, ongoing advancements in gene editing technologies such as CRISPR/Cas9 and other gene-editing tools offer potential for curative treatments of Duchenne muscular dystrophy. The development of personalized medicine approaches tailored to individual genetic profiles may improve efficacy and minimize side effects, generating opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.57 billion
Estimated Year [2024]	USD 1.70 billion
Forecast Year [2030]	USD 2.80 billion
CAGR (%)	8.61%

Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy

Casimersen is approved for treating DMD in patients with a confirmed mutation due to exon 45 skipping. This need-based preference for casimersen is critical for patients with a specific genetic makeup, providing a targeted treatment option. Deflazacort ensures efficacy in delaying disease progression and improving muscle strength to slow the progression of DMD across a broad range of patients, regardless of their specific genetic mutation. Delandistrogene Moxeparvovec (Roctavian) gene therapy is designed for patients that benefit from a direct approach to correcting the gene defect responsible for DMD. Eteplirsen (Exondys 51) is preferred for DMD patients observing confirmed mutation of the DMD gene due to exon 51 skipping. Golodirsen meets the needs of a niche patient group, offering a targeted genetic treatment with a specific genetic mutation amenable to exon 53 skipping. Viltolarsen is approved for DMD patients amenable to exon 53 skipping that targets a specific genetic alteration, providing a precision medicine approach for affected patients.

End-Use: Increasing adoption of DMD drugs in ambulatory centers

Ambulatory centers, also known as outpatient care centers, provide medical services to patients that do not require hospital admission. Ambulatory center facilities have been increasingly preferred for routine check-ups, diagnosis, and the management of chronic conditions such as DMD due to their convenience and cost-effectiveness. Homecare settings represent a rapidly growing segment that caters to the preference for receiving healthcare services, including DMD drug treatments, in the patient's home. Homecare settings allow for continuous, personalized care and the administration of DMD medications in the comfort of the patient's home.

Regional Insights

In the Americas region, the United States and Canada are pivotal due to the strong presence of key players engaged in developing Duchenne Muscular Dystrophy (DMD) drugs. The Americas region is characterized by high consumer awareness, substantial investments in R&D, and favorable government policies. The United States holds a key position in developing breakthrough therapies and has several patents filed for innovative DMD treatments. Canada demonstrates strong governmental support and public-private partnerships, fostering growth in the market arena. The European Union countries are at the forefront regarding regulatory support for DMD drug development and have several initiatives supporting research and access to treatment. Patent activity is high in the EMEA region, with several countries contributing to discoveries. The Middle East region, although smaller in terms of market size, is witnessing increased investment and growing awareness. Africa faces challenges related to healthcare infrastructure and treatment access and shows potential for growth through international partnerships and investments. The Asia Pacific region, especially China, Japan, and India, has grown significantly in the DMD drugs market. The market growth in the APAC countries is attributed to increasing awareness, governmental initiatives, and improving healthcare infrastructure. Research and investment in APAC countries have been robust, with Japan leading in innovative therapies and patent filings. China and India are rapidly advancing in research and offering cost-effective treatments, significantly affecting market dynamics and customer purchasing behaviors.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Duchenne Muscular Dystrophy Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Duchenne Muscular Dystrophy Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Duchenne Muscular Dystrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Anuh Pharma Limited, Arlak Biotech Pvt.Ltd., Aurigene Pharmaceutical Services Ltd., Bayer Pharmaceutical, Cipla Inc., Enomark, Glasier Wellness, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Leo Pharma, Lifecare Neuro Products Limited, Mankind Pharma Ltd., Merck & Co., Inc.,, MODASA Pharmaceuticals Pvt. Ltd., Novartis AG, Pfizer Inc., QndQ Derma, RayBiotech, Inc., Ronyd Healthcare Pvt Ltd., Sarepta Therapeutics, Inc., Sumitomo Corporation, Texas Pharmaceuticals Pvt. Ltd., Wallace Pharmaceuticals Pvt Ltd., Wellona Pharma, and Zuventus Healthcare Ltd..

Market Segmentation & Coverage

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Casimersen
- Deflazacort
- Delandistrogene Moxeparvovec
- Eteplirsen
- Golodirsen
- Viltolarsen

Administration Method
- Oral
- Parental

End-Use
- Ambulatory Centres
- Homecare Settings
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Duchenne Muscular Dystrophy Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Duchenne Muscular Dystrophy Drugs Market?

3. What are the technology trends and regulatory frameworks in the Duchenne Muscular Dystrophy Drugs Market?

4. What is the market share of the leading vendors in the Duchenne Muscular Dystrophy Drugs Market?

5. Which modes and strategic moves are suitable for entering the Duchenne Muscular Dystrophy Drugs Market?

Product Code: MRR-5E3B35529469

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
  - 5.1.1.2. Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
- 5.1.2. Restraints
  - 5.1.2.1. High costs of DMD drug therapies
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
  - 5.1.3.2. Development of personalized medicine approaches tailored to individual genetic profiles
- 5.1.4. Challenges
  - 5.1.4.1. Limited awareness and side affects associated with DMD drugs
5.2. Market Segmentation Analysis
- 5.2.1. Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy
- 5.2.2. End-Use: Increasing adoption of DMD drugs in ambulatory centers
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Duchenne Muscular Dystrophy Drugs Market, by Drug Type

6.1. Introduction
6.2. Casimersen
6.3. Deflazacort
6.4. Delandistrogene Moxeparvovec
6.5. Eteplirsen
6.6. Golodirsen
6.7. Viltolarsen

7. Duchenne Muscular Dystrophy Drugs Market, by Administration Method

7.1. Introduction
7.2. Oral
7.3. Parental

8. Duchenne Muscular Dystrophy Drugs Market, by End-Use

8.1. Introduction
8.2. Ambulatory Centres
8.3. Homecare Settings
8.4. Hospitals & Clinics

9. Americas Duchenne Muscular Dystrophy Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Agamree Receives FDA Approval as First "Dissociative Steroidal Anti-Inflammatory" to Treat Duchenne Muscular Dystrophy
- 12.3.2. FDA Approves a New Steroidal-Type Anti-Inflammatory Drug for Duchenne Muscular Dystrophy
- 12.3.3. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio